ALX ONCOLOGY HOLDINGS INC (ALXO) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-17

Key Insights

The reporting person, Jeff E. Knight, who is the Chief Development and Operating Officer of ALX Oncology Holdings Inc., has acquired 800,000 stock options to purchase the company's common stock at an exercise price of $1.68 per share.
The stock options vest over 4 years, with 1/4th of the shares vesting on April 13, 2027 and the remaining shares vesting monthly thereafter.
This significant acquisition of stock options by a key executive suggests the reporting person's confidence in the company's future and their alignment with shareholder interests.

Want the newest filings?

This analysis covers the filing from 2026-04-17. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-17

The reporting person, Barbara Klencke, acquired 100,000 stock options of ALX Oncology Holdings Inc. (ALXO) on April 16, 2026, with a strike price of $1.68 and a 10-year expiration date.
The options vest over a 4-year period, with 1/4th vesting on February 25, 2027 and the remaining vesting monthly thereafter.
This insider purchase suggests that the Chief Medical Officer is bullish on the company's prospects and believes the stock is currently undervalued.

Filed: 2026-03-23

Insider Jason Lettmann, the CEO of ALX Oncology Holdings, sold 12,311 shares of common stock on March 19, 2026 for $2.17 per share, likely to satisfy tax obligations from the vesting of performance-based restricted stock units.
After the sale, Lettmann still holds a significant direct ownership stake of 293,609 shares, indicating his continued alignment with shareholders.
The stock sale appears to be a routine transaction to cover tax liabilities and not a broader bearish signal, as Lettmann maintains a substantial equity position in the company.

Filed: 2026-03-23

The reporting person, Shelly Pinto, sold 903 shares of common stock in ALX Oncology Holdings Inc. (ALXO) on March 19, 2026 to satisfy tax obligations related to the vesting of performance-based restricted stock units.
Following the reported transaction, the reporting person continues to hold a direct ownership of 86,805 shares of common stock in the company.
The sale of shares by an insider, particularly to cover tax obligations, could be seen as a neutral signal as it does not necessarily indicate a broader change in the insider's view of the company's prospects.

Filed: 2026-02-20

Shelly Pinto, the SVP of Finance and CAO, sold 565 shares of ALX Oncology Holdings Inc. (ALXO) on February 18, 2026 at $2.27 per share. This sale was likely to satisfy tax obligations related to the vesting of restricted stock units.
Following the reported transaction, Pinto now beneficially owns 87,708 shares of ALXO, indicating she continues to hold a significant position in the company.
Insider selling, even for tax purposes, can sometimes be viewed negatively by investors, as it may signal management's lack of confidence in the company's future performance.

Filed: 2026-02-04

Corey S. Goodman, a director and 10% owner of ALX Oncology Holdings Inc., acquired a significant number of 3,184,713 common shares at $1.57 per share, indicating strong confidence in the company's prospects.
The filing also reveals Goodman's indirect beneficial ownership of additional 4,598,970 shares through various investment vehicles, suggesting he has a substantial stake in the company.
The large insider purchase, representing a significant increase in Goodman's ownership position, could signal positive developments or growth opportunities at ALX Oncology that the director believes will drive shareholder value.

Filed: 2026-01-28

Insider Harish Shantharam has been granted a stock option to acquire 303,000 shares of ALX Oncology common stock, vesting over 4 years. This indicates management's confidence in the company's long-term prospects.
The exercise price of $1.48 per share suggests the option was granted at the current market price, aligning Harish's incentives with shareholders.
As Chief Financial Officer, Harish's equity grant signals an important leadership change and potential strategic direction for the company.

Filed: 2026-01-28

Shelly Pinto, the Senior Vice President of Finance and Chief Accounting Officer, was granted a stock option to purchase 192,000 shares of ALX Oncology Holdings Inc. (ALXO) common stock at an exercise price of $1.48 per share.
The stock option vests in 48 equal monthly installments starting February 26, 2026, aligning Pinto's incentives with long-term shareholder value creation.
Insider transactions, such as this stock option grant, can provide insights into management's confidence in the company's future prospects and their commitment to the business.

Filed: 2026-01-28

The CEO Jason Lettmann acquired 912,000 stock options at an exercise price of $1.48, indicating his confidence in the company's future performance.
The options vest over a 4-year period, aligning Lettmann's incentives with long-term shareholder value creation.
Insider buying of this magnitude is a positive signal, as it suggests the CEO believes the stock is undervalued and expects the company to perform well.

Filed: 2026-01-21

Corey S. Goodman, a director and 10% owner of ALX Oncology Holdings Inc (ALXO), acquired 40,400 stock options with an exercise price of $1.32, vesting over 12 months starting February 2026.
The insider acquisition of a sizable option position suggests Goodman's confidence in the company's future prospects and alignment with shareholder interests.
The timing of the option grant, shortly before the reported transaction date, indicates potential strategic planning around equity incentives for key personnel.

Filed: 2026-01-21

The reporting person, J. Scott Garland, acquired 40,400 stock options with an exercise price of $1.32 and a vesting period of 12 months, indicating potential insider confidence in the company's future performance.
The option grant suggests the company may be incentivizing its directors to align their interests with those of shareholders through equity-based compensation.
Insider transactions can provide insights into management's outlook on the company's prospects, though further analysis of the broader context would be needed to fully assess the significance.

Filed: 2026-01-21

The reporting person, Alan B. Sandler, a director of ALX Oncology Holdings Inc., has acquired 10,100 stock options with an exercise price of $1.32 and a vesting period of 12 months.
This insider transaction suggests that Sandler has a positive outlook on the company's future and is willing to invest in its equity.
The stock option grant represents a long-term commitment to the company, potentially aligning Sandler's interests with those of other shareholders.

Filed: 2026-01-21

Insider Daniel J. Curran, a director of ALX Oncology, acquired 16,833 stock options with an exercise price of $1.32, vesting over 12 months. This could signal his confidence in the company's future prospects.
The stock option grant suggests the company is providing equity-based incentives to its directors to align their interests with those of shareholders.
Investors should monitor Curran's future transactions and whether other insiders also participate in similar option grants, as it could indicate management's belief in the company's growth potential.

Filed: 2026-01-21

This Form 4 filing indicates that Chris H. Takimoto, a director of ALX Oncology Holdings Inc., has acquired 40,400 stock options with an exercise price of $1.32 and a vesting period of 12 months. This suggests the company is incentivizing its board members to align their interests with shareholders.
The timing of this option grant, coming in January 2026, may indicate the company is entering a critical phase of development or commercialization, where strong leadership and strategic guidance from the board will be crucial.
The relatively low exercise price of $1.32 compared to the current stock price could make these options attractive to the director, potentially signaling their confidence in the company's future performance.

Filed: 2026-01-21

Rekha Hemrajani, a director of ALX Oncology Holdings, acquired 40,400 stock options with an exercise price of $1.32 and a 10-year term, indicating their belief in the company's long-term prospects.
The options vest in 12 equal monthly installments starting in February 2026, suggesting a commitment to the company and confidence in its future performance.
This insider transaction could signal positive sentiment towards ALX Oncology's strategic direction and growth potential.

Other reports for ALX ONCOLOGY HOLDINGS INC

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.